AstraZeneca shares oncology data at ASCO 2023
Betsy Goodfellow | May 25, 2023 | News story | Medical Communications | ASCO, AstraZeneca, Cancer, Oncology, oncology
AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting on 2-6 June 2023.
The company plans to share 130 abstracts ‒ featuring 22 approved and potential new medicines across its oncology portfolio and pipeline ‒ with various presentations planned, including one to share overall survival (OS) results from the ADAURA phase 3 trial of Tagrisso (osimertinib) in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated (EGFRm) lung cancer.
Other drugs they will present include Enhertu for a range of advanced HER2-expressing advanced cancers, and Lynparza and Imfinzi in combination to delay progression in newly diagnosed advanced ovarian cancer without a tumour BRCA mutation.
Dave Fredrickson, executive vice president of the Oncology Business Unit at AstraZeneca, commented: “Our unwavering commitment to continually raising the standard of cancer care for patients with high unmet needs is evident in our data at ASCO this year. With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. We will showcase significant steps toward that goal with overall survival data from ADAURA that reinforce Tagrisso as the backbone therapy in EGFR-mutated lung cancer.”
Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca, added: “We are extending the benefits of our practice-changing cancer medicines, including Tagrisso, Imfinzi and Lynparza, while also investing in new scientific platforms such as T-cell engagers and cell therapy to attack cancer from multiple angles and advance the next wave of options for patients. At ASCO, the extraordinary momentum for our antibody drug conjugate (ADC) collaboration portfolio continues with data for Enhertu underscoring its potential across many HER2-expressing tumour types beyond breast, lung and gastric, and updated results for datopotamab deruxtecan that reinforce our confidence in this TROP2-directed treatment.”
Betsy Goodfellow
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
Bio-Rad signs exclusive European distribution deal with Gencurix for oncology testing kits
The agreement expands access to oncology testing kits across Europe
